Posted 16 October, 2023

BioNexus Gene Lab Corp appointed Chi Yuen Leong as new CEO

Nasdaq:BGLC appointed new Chief Executive Officer Chi Yuen Leong in a 8-K filed on 16 October, 2023.

  Appointment of Chi Yuen Leong as Chief Executive Officer and Director.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of BioNexus Gene Lab Corp
Health Care/Life Sciences • Biotechnology
BioNexus Gene Lab Corp. is a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.
Market Cap
View Company Details
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chi Yuen Leong as Chief Executive Officer and Director.

On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. ("the Company") approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.

Mr. Leong has no family relationship with any director or executive officer of the Company. He was not involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

Mr. Leong, aged 72, has extensive experience in management, commercialization, finance, and the biotechnology industry. He served as the President and director from the Company's inception to August 2022 and has been working with and guiding the Company's successful listing on OTC and Nasdaq. He joined the US Arem Pacific Corporation as the Chief Executive Officer from March 1, 2009, until September 30, 2015. Mr. Leong received a Bachelor of Behavioral Sciences from the University of East Asia, Malaysia. Mr. Leong brings a wide range of business experience, including experience with public companies, to our board of directors. 

Mr. Leong entered into an employment agreement with the Company dated October 12, 2023, and agreed to receive an annual compensation of $24,000.